---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-024348"
form_type: "8-K/A"
ticker: "BCPC"
cik: "0000009326"
company_name: "BALCHEM CORP"
filed_at: "2022-09-06T23:59:59+00:00"
generated_at: "2026-06-23T16:08:03.898504+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Balchem files Kappa bioscience financials: 2021 revenue NOK 241M, net profit NOK 14.6M

## Summary
- Kappa (Kechu Bidco) 2021: revenue NOK 240.9M, op. profit NOK 42.7M, net profit NOK 14.6M including NOK 26.7M discontinued ops loss.
- Total assets NOK 1,059M, equity NOK 594M, borrowings NOK 245M, cash NOK 100M as of Dec 31, 2021.
- Unaudited pro forma combined financials for FY2021 and H1 2022 also filed, reflecting acquisition.
- Audit opinion qualified for omission of comparative info; prepared per IFRS for SEC Rule 3-05.
- Discontinued ops loss of NOK 26.7M from Kappa Ingredients GmbH (deconsolidated Nov 2021).

## SEC filing metadata
- accession: 0001628280-22-024348
- form_type: 8-K/A
- ticker: BCPC
- cik: 0000009326
- company_name: BALCHEM CORP
- filed_at: 2022-09-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/9326/000162828022024348/0001628280-22-024348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/9326/000162828022024348/bcpc-20220621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-024348
- JSON: https://secwatch.observer/filing/0001628280-22-024348.json
- Plain text: https://secwatch.observer/filing/0001628280-22-024348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.